# IL TRATTAMENTO NUTRIZIONALE DELLO SCOMPENSO CARDIACO

Giorgio Bedogni

### **Obiettivo**

 Discutere la base di evidenza disponibile per il trattamento nutrizionale dello scompenso cardiaco e la sua implementazione in forma di linee guida per la pratica professionale (Academy of Nutrition and Dietetics, AND ex American Dietetic Association, ADA)

# Cosa è lo scompenso cardiaco?





2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation 2009 WRITING GROUP TO REVIEW NEW EVIDENCE AND UPDATE THE 2005 GUIDELINE FOR THE MANAGEMENT OF PATIENTS WITH CHRONIC HEART FAILURE WRITING ON BEHALF OF THE 2005 HEART FAILURE WRITING COMMITTEE, Mariell Jessup, William T. Abraham, Donald E. Casey, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Marvin A. Konstam, Donna M. Mancini, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson and Clyde W. Yancy

Circulation. 2009;119:1977-2016; originally published online March 26, 2009; doi: 10.1161/CIRCULATIONAHA.109.192064

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 2009 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7322. Online ISSN: 1524-4539

# Cosa è lo scompenso cardiaco?

- Definizione
  - Sindrome da alterata funzione ventricolare
- Prevalenza (USA)
  - 2% 40-59 anni; 5% 60-69 anni; > 10% > 70 anni
- Cause
  - Cardiopatia ischemica, cardiopatia ipertensiva (...)

Hunt SA *et al. Circulation* 2009;**119**:1977. http://www.nhlbi.nih.gov

# Cosa è lo scompenso cardiaco?

- Sintomi
  - Dispnea, fatica ed idroritenzione (...)
- Prognosi
  - Compromissione funzionale variabile
  - Mortalità elevata (2/3 a 5 anni dalla diagnosi)

Hunt SA *et al. Circulation* 2009;**119**:1977. http://www.nhlbi.nih.gov

### At Risk for Heart Failure **Heart Failure** STAGE A STAGE D STAGE B STAGE C Refractory HF At high risk for HF Structural heart Structural heart disease but without structural requiring specialized disease but without with prior or current interventions. heart disease or signs or symptoms of symptoms of HF. symptoms of HF. HF. e.g.: Patients who have marked e.g.: Patients with: symptoms at rest -hypertension e.g.: Patients with: e.g.: Patients with: despite maximal -atherosclerotic disease -known structural -previous MI medical therapy -diabetes heart disease Refractory -LV remodeling (e.g., those who are Structural Development -obesity and including LVH and symptoms of recurrently of symptoms heart -metabolic syndrome -shortness of low EF HF at rest hospitalized or of HF disease breath and fatigue, or -asymptomatic cannot be safely reduced exercise Patients valvular disease discharged from the -using cardiotoxins tolerance hospital without -with FHx CM specialized interventions) **THERAPY THERAPY** THERAPY **THERAPY** GOALS -All measures under Stages A and B **GOALS GOALS** -Dietary salt restriction -All measures under Stage A GOALS -Treat hypertension -Encourage smoking -Appropriate measures DRUGS FOR under Stages A, B, C cessation DRUGS ROUTINE USE -Treat lipid disorders -ACEI or ARB in appropriate -Decision re: appropriate -Diuretics for fluid retention -Encourage regular level of care patients (see text) -ACEI exercise - Beta-blockers in -Beta-blockers OPTIONS Discourage alcohol appropriate patients intake, illicit drug use -Compassionate end -of-(see text) DRUGS IN -Control metabolic life care/hospice SELECTED PATIENTS syndrome -Extraordinary measures -Aldosterone antagonist heart transplant -ARBs DRUGS chronic inotropes -Digitalis -ACEI or ARB in permanent -Hydralazine/nitrates appropriate patients mechanical support experimental (see text) for vascular **DEVICES IN** disease or diabetes surgery or drugs SELECTED PATIENTS -Biventricular pacing Implantable defibrillators

Hunt SA et al. Circulation 2009;119:1977.

### At Risk for Heart Failure

Structural

heart

disease

### **Heart Failure**

# STAGE A At high risk for HF but without structural heart disease or symptoms of HF. e.g.: Patients with: -hypertension -atherosclerotic disease -diabetes -obesity -metabolic syndrome

or

-using cardiotoxins

-with FHx CM

**Patients** 

# THERAPY

### **GOALS**

- -Treat hypertension
- Encourage smoking cessation
- -Treat lipid disorders
- -Encourage regular exercise
- -Discourage alcohol
- intake, illicit drug use -Control metabolic syndrome

### DRUGS

-ACEI or ARB in appropriate patients (see text) for vascular disease or diabetes

### STAGE B

Structural heart disease but without signs or symptoms of HF.

### e.g.: Patients with:

- -LV remodeling including LVH and low EF
- -asymptomatic valvular disease

**THERAPY** 

GOALS

-All measures under Stage A

DRUGS

-ACEI or ARB in appropriate

patients (see text)

appropriate patients

- Beta-blockers in

(see text)

### STAGE C

Structural heart disease with prior or current symptoms of HF.

# e.g.: Patients with: -known structural heart disease

and
-shortness of
breath and fatigue,
reduced exercise
tolerance

ath and fatigue, IIII HF at uced exercise

symptoms of HF at rest

Refractory

### **THERAPY**

### GOALS

- -All measures under Stages A and B
- -Dietary salt restriction

### DRUGS FOR ROUTINE USE

- -Diuretics for fluid retention
- -ACEI

Development

of symptoms

of HF

-Beta-blockers

### DRUGS IN SELECTED PATIENTS

- -Aldosterone antagonist
- -ARBs
- -Digitalis
- -Hydralazine/nitrates

### DEVICES IN SELECTED PATIENTS

-Biventricular pacing Implantable defibrillators

### STAGE D

Refractory HF requiring specialized interventions.

e.g.: Patients
who have marked
symptoms at rest
despite maximal
medical therapy
(e.g., those who are
recurrently
hospitalized or
cannot be safely
discharged from the
hospital without
specialized
interventions)

### **THERAPY**

### GOALS

-Appropriate measures under Stages A, B, C -Decision re: appropriate level of care

### OPTIONS

- -Compassionate end -oflife care/hospice
- -Extraordinary measures
  - heart transplantchronic inotropes
  - permanent mechanical support
  - experimental surgery or drugs

- Trattare ipertensione
- Trattare dislipidemia
- Trattare diabete
- Incoraggiare sospensione fumo
- Incoraggiare attività fisica
- Scoraggiare consumo di alcool
- Controllare la sindrome metabolica

• "... should be controlled according to contemporary guidelines".

Hunt SA et al. Circulation 2009;**119**:1977.

- Trattare ipertensione
- Trattare dislipidemia
- Trattare diabete
- Incoraggiare sospensione fumo
- Incoraggiare attività fisica
- Scoraggiare consumo di alcool
- Controllare la sindrome metabolica

### Attività fisica




Figure 2 The association between walking and all-cause mortality in men and women. The referent group refers to the lowest walking (volume/intensity) group and hazard ratios of less than 1.0 suggest benefits of walking. MET, metabolic equivalent.

Hamer M et al. Br J Sports Med 2008;42:238 (systematic review of cohort studies).

### Attività fisica

"Physical activity decreased all-cause mortality in patients with coronary heart disease (odds ratio = 0.73, 95% confidence interval 0.54 to 0.98)"

Karmisholt K. Dan Med Bull 2005;52:90 (systematic review of randomized controlled trials).

- Trattare ipertensione
- Trattare dislipidemia
- Trattare diabete
- Incoraggiare sospensione fumo
- Incoraggiare attività fisica
- Scoraggiare consumo di alcool
- Controllare la sindrome metabolica

Journal of the American College of Cardiology © 2007 by the American College of Cardiology Foundation Published by Elsevier Inc. Vol. 50, No. 11, 2007 ISSN 0735-1097/07/\$32.00 doi:10.1016/j.jacc.2007.04.089


### **STATE-OF-THE-ART PAPER**


### **Alcohol and Cardiovascular Health**

The Razor-Sharp Double-Edged Sword

James H. O'Keefe, MD, FACC,\* Kevin A. Bybee, MD,\* Carl J. Lavie, MD, FACC† Kansas City, Missouri; and New Orleans, Louisiana

O'Keefe et al. J Am Coll Cardiol 2007;50:1009.







 "Until we have more randomized outcome data, and tools for predicting susceptibility to problem drinking, it would seem prudent to encourage physicians and patients to focus on more innocuous interventions to prevent CHD"


O'Keefe et al. J Am Coll Cardiol 2007;50:1009.



### **ALCOHOL CONFUSION**

# What is a unit?

Seabrook R *BMJ* 2007;17;335:1008.



• Come per lo stadio A

### At Risk for Heart Failure **Heart Failure** STAGE A STAGE D STAGE B STAGE C Refractory HF At high risk for HF Structural heart Structural heart disease but without structural requiring specialized disease but without with prior or current interventions. heart disease or signs or symptoms of symptoms of HF. symptoms of HF. HF. e.g.: Patients who have marked e.g.: Patients with: symptoms at rest -hypertension e.g.: Patients with: e.g.: Patients with: despite maximal -atherosclerotic disease -known structural -previous MI medical therapy heart disease -diabetes Refractory -LV remodeling (e.g., those who are Structural Development -obesity and including LVH and symptoms of recurrently of symptoms heart -shortness of -metabolic syndrome HF at rest low EF hospitalized or disease of HF breath and fatigue, or -asymptomatic cannot be safely reduced exercise Patients valvular disease discharged from the -using cardiotoxins tolerance hospital without -with FHx CM specialized interventions) **THERAPY THERAPY** THERAPY **THERAPY** GOALS -All measures under Stages A and B **GOALS** GOALS -Dietary salt restriction -All measures under Stage A GOALS -Treat hypertension -Encourage smoking -Appropriate measures DRUGS FOR under Stages A, B, C cessation DRUGS ROUTINE USE -Treat lipid disorders -ACEI or ARB in appropriate -Decision re: appropriate -Diuretics for fluid retention -Encourage regular level of care patients (see text) -ACEI exercise - Beta-blockers in -Beta-blockers OPTIONS Discourage alcohol appropriate patients intake, illicit drug use -Compassionate end -of-(see text) DRUGS IN -Control metabolic life care/hospice SELECTED PATIENTS syndrome -Extraordinary measures -Aldosterone antagonist heart transplant -ARBs DRUGS chronic inotropes -Digitalis -ACEI or ARB in permanent -Hydralazine/nitrates appropriate patients mechanical support experimental (see text) for vascular **DEVICES IN** disease or diabetes surgery or drugs SELECTED PATIENTS -Biventricular pacing Implantable defibrillators

- Come per gli stadi A e B
- + Restrizione di sodio

### At Risk for Heart Failure

### **Heart Failure**

### STAGE A STAGE D STAGE B STAGE C Refractory HF At high risk for HF Structural heart Structural heart disease but without structural requiring specialized disease but without with prior or current interventions. heart disease or signs or symptoms of symptoms of HF. symptoms of HF. HF. e.g.: Patients who have marked e.g.: Patients with: symptoms at rest -hypertension e.g.: Patients with: e.g.: Patients with: despite maximal -atherosclerotic disease -known structural -previous MI medical therapy heart disease -diabetes Refractory -LV remodeling (e.g., those who are Structural Development -obesity and including LVH and symptoms of recurrently of symptoms heart -metabolic syndrome -shortness of low EF HF at rest hospitalized or of HF disease breath and fatigue, or -asymptomatic cannot be safely reduced exercise Patients valvular disease discharged from the -using cardiotoxins tolerance hospital without -with FHx CM specialized interventions) **THERAPY THERAPY** THERAPY **THERAPY** GOALS -All measures under Stages A and B **GOALS** GOALS -Dietary salt restriction -All measures under Stage A GOALS -Treat hypertension -Encourage smoking -Appropriate measures DRUGS FOR under Stages A, B, C cessation DRUGS ROUTINE USE -Treat lipid disorders -ACEI or ARB in appropriate -Decision re: appropriate -Diuretics for fluid retention -Encourage regular level of care patients (see text) -ACEI exercise - Beta-blockers in -Beta-blockers OPTIONS Discourage alcohol appropriate patients intake, illicit drug use -Compassionate end -of-(see text) DRUGS IN -Control metabolic life care/hospice SELECTED PATIENTS syndrome -Extraordinary measures -Aldosterone antagonist heart transplant -ARBs DRUGS chronic inotropes -Digitalis -ACEI or ARB in permanent -Hydralazine/nitrates appropriate patients mechanical support experimental (see text) for vascular **DEVICES IN** disease or diabetes surgery or drugs SELECTED PATIENTS -Biventricular pacing

Implantable defibrillators

- Come per gli stadi A, B e C
- + Restrizione di sodio

### Restrizione di sodio

- Lo scopo è ridurre l'idroritenzione facilitando l'azione dei diuretici (e degli altri farmaci antipertensivi)
- La quantità di sodio consigliata è 3-4\* g nello stadio C e 2 g nello stadio D

<sup>\*</sup> in (parziale) contraddizione con le linee guida JNC VII per l'ipertensione


# Restrizione di sodio



www.giorgiobedogni.it

### At Risk for Heart Failure


### **Heart Failure**



# Tutti gli stadi

 Nessuna indicazione alla supplementazione routinaria di macro- o micro-nutrienti

# Heart failure evidence-based practice guidelins



### **MNT** and Heart Failure

Referral to a registered dietitian for MNT is recommended whenever an individual has heart failure. A planned initial visit lasting at least 45 minutes and at least one to three planned follow-up visits (at least 30 minutes each) can lead to improved dietary pattern and quality of life and decreases in edema and fatigue. Along with optimal pharmacological management, MNT may also reduce hospitalizations.

Strong, Imperative

### **Proteins**

• In assessing protein needs for patients with heart failure, clinically stable depleted patients should have a daily intake of at least 1.37 g protein/kg and normally nourished patients should have a daily intake 1.12 g protein/kg in order to preserve their actual body composition or limit the effects of hypercatabolism. Research indicates that HF patients have significantly higher protein needs than those without HF, as measured by negative nitrogen balance.

# **Energy**

 In assessing energy needs for patients with heart failure, the majority of studies indicate that use of indirect calorimetry best determines energy needs. When indirect calorimetry is not possible consider starting with usual predictive equations and adjusting for increased catabolic state.

# **Fluid**

 For patients with heart failure, fluid intake should be between 1.4 and 1.9 L (48-64 oz.) per day, depending on clinical symptoms (i.e. edema, fatigue, shortness of breath). Fluid restriction will improve clinical symptoms and quality of life.

### Sodium

- For patients with heart failure, sodium intake should be less than 2000 mg (2 g) per day. Sodium restriction will improve clinical symptoms (i.e. edema, fatigue) and quality of life.
- \*Attenzione all'aumento di mortalità potenzialmente conseguente alla restrizione di sodio

### Folate and B12

The practitioner should encourage patients with HF to consume at least the DRI for folate through food and/or a combination of B6, B12, and folate supplementation. Folate supplementation given with other vitamins/minerals has been shown to have beneficial clinical HF outcomes.

# **Thiamine Supplementation**

Since diurectic use can lead to thiamine deficiency in patients with heart failure (HF), then the practitioner should evaluate thiamine status. The practitioner should encourage the patient to consume at least the DRI through food and/or supplements. The practitioner should stay alert to future research involving thiamine.

Fair, Conditional

Current limited evidence does not justify encouraging those who do not drink alcohol to start doing so. If a patient currently drinks alcohol, and if not contraindicated, then a maximum of one drink per day for women and up to two drinks per day for men may be tolerated. This level of alcohol consumption has been demonstrated to not be harmful in heart failure patients.

Fair, Conditional

# L-Arginine, Carnitine, Coenzyme Q10 and Hawthorn

If a patient inquires about or is currently taking L-arginine, carnitine, coenzyme Q10 or hawthorn supplements, then the practitioner may discuss the limited evidence available regarding clinical heart failure outcomes. Research is inconclusive. The practitioner should stay alert to future research involving these supplements.

Weak, Conditional

# **Magnesium Supplementation**

The practitioner should encourage patients with heart failure (HF) to consume at least the DRI for magnesium through food and/or supplements. Low levels of magnesium may be present in patients with heart failure and irregular heart rhythms may occur. The practitioner should stay alert to future research involving magnesium.

Fair, Conditional

# Grazie